Validation of the “Six-and-Twelve” Prognostic Score in Transarterial Chemoembolization–Treated Hepatocellular Carcinoma Patients

The “six-and-twelve” prognostic score was proposed recently to predict survival rate in patients with unresectable hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE). However, it has not been validated externally. We validated this score and previous prognostic scores in Thai HCC patients treated with TACE. METHODS: We identified all HCC patients who underwent TACE between January 2007 and December 2018 at our hospital. The inclusion criteria were treatment-naive, unresectable HCC BCLC-A and BCLC-B; if cirrhosis was present, Child-Pugh score ≤7; and baseline performance status 0–1. RESULTS: Of 716 HCC patients undergoing TACE, 281 (mean age, 61.1 years; 73.0% men, 92.2% with cirrhosis) were eligible. Approximately half of the patients had hepatitis B virus. Median overall survival was 20.3 (95% confidence interval, 16.4–26.3) months. By stratifying with the “six-and-twelve” score (≤6, >6–12, >12), median (95% confidence interval) overall survival was 35.1 (26.4–53.0), 16.0 (11.6–22.6), and 7.6 (5.4–14.9) months, respectively. Area under the receiver operating characteristic curves (AUROCs) predicting death at 1, 2, and 3 years for the “six-and-twelve” score were 0.714, 0.700, and 0.688, respectively. Compared with the other currently available scores, the AUROC predicting death at 1 year for the “six-and-twelve” score was the most predictive and better than other models except the up-to-seven model. DISCUSSION: Our study confirms the value of the “six-and-twelve” score to predict survival rate of unresectable HCC treated with TACE. However, in our validation cohort, AUROC of the “six-and-twelve” score was slightly lower than that of the original Chinese cohort (0.73).